Product Description
Mechanisms of Action: TXA2 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for Terbogrel](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT02223494 | P2 |
Terminated |
Familial Primary Pulmonary Hypertension|Hypertension, Pulmonary |
2000-03-01 |
|
NCT02223481 | P2 |
Completed |
Familial Primary Pulmonary Hypertension|Hypertension, Pulmonary |
1999-09-01 |
|
NCT02222987 | P1 |
Completed |
Healthy Volunteers |
1999-03-01 |